INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Trex Company, Inc. - TREX

NEW YORK, November 12, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Trex Company, Inc. (“Trex” or the “Company”) (NYSE: TREX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Trex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 4, 2025, Trex released its third quarter 2025 financial results, which missed consensus estimates.  Among other items, Trex reported a 12% decline in net income per share and said that it expects a “muted” fourth quarter, explaining that it expects its “channel partners to lower their inventories through the rest of the year.” 

On this news, Trex’s stock price fell $14.61 per share, or 31.1%, to close at $32.43 per share on November 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alaska Air Group, Inc. - ALK

NEW YORK, November 11, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Alaska Air Group, Inc. (“Alaska Air” or the “Company”) (NYSE: ALK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Alaska Air and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 23, 2025, Alaska Airlines disclosed that it was “experiencing an IT outage that has resulted in a systemwide ground stop of Alaska and Horizon Air flights across our network, causing delays and cancellations.” 

On this news, Alaska Air’s stock price fell $2.86 per share, or 6.13%, to close at $43.77 per share October 24, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plc - BCYC

NEW YORK, November 11, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Bicycle Therapeutics plc (“Bicycle” or the “Company”) (NASDAQ: BCYC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Bicycle and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 31, 2025, RBC Capital Markets analyst Leonid Timashev downgraded Bicycle to Sector Perform from Outperform, citing delays in development of zelenectide pevedotin, which is in phase 2/3 development for metastatic urothelial cancer, due to pushing dose selection to the first quarter of 2026.  Timashev noted that the urothelial cancer treatment space is growing more competitive, and asserted that any further delays from Bicycle will only help sales of a competing Pfizer product. 

Following the downgrade, Bicycle’s American Depositary Receipt (“ADR”) price fell $0.69 per ADR, or 7.88%, to close at $8.07 per ADR on October 31, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of The Bancorp, Inc. - TBBK

NEW YORK, November 11, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  The Bancorp, Inc. (“Bancorp” or the “Company”) (NASDAQ: TBBK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Bancorp and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 30, 2025, Bancorp issued a press release reporting its financial results for the third quarter of 2025.  In the press release, Bancorp’s Chief Executive Officer stated, in relevant part: “We are lowering guidance from $5.25 to $5.10 earnings per share for 2025, primarily due to lower projected balances for our traditional lending businesses and an increased credit provision for leasing as a result of losses on the disposition of previously identified credits in trucking.  In addition, we are not giving specific guidance for 2026 other than we are targeting a minimum $7 earnings per share run-rate by the fourth quarter of 2026.” 

On this news, Bancorp’s stock price fell $11.83 per share, or 15.32%, to close at $65.37 per share on October 31, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Surgery Partners, Inc. - SGRY

NEW YORK, November 11, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Surgery Partners, Inc. (“Surgery Partners” or the “Company”) (NASDAQ: SGRY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Surgery Partners and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 10, 2025, Surgery Partners issued a press release announcing its financial results for the third quarter of 2025 and held an earnings call to discuss the same.  The Company lowered its full-year revenue guidance to a range of $3.275 billion to $3.3 billion, and its adjusted EBITDA guidance to a range of $535 million to $540 million.  Surgery Partners’ management attributed the guidance revision to timing delays in capital deployment, lost earnings from ambulatory surgical center divestitures, and a cautious stance on commercial payer mix and volume in the fourth quarter. 

On this news, Surgery Partners’ stock price fell $5.47 per share, or 25.42%, to close at $16.04 per share on November 10, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation - ENVX

NEW YORK, November 7, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Enovix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 5, 2025, Enovix issued a press release announcing its financial results for the third quarter of 2025 and hosted an earnings call to discuss the same.  During the call, Enovix’s management revealed that the Chinese smartphone manufacturer Honor was its leading prospective customer, but disclosed that the battery samples that Enovix shipped to Honor earlier in the year failed to achieve Honor’s life-cycle specifications, necessitating additional chemistry changes with new samples now expected to be shipped later this quarter.  As a result, Enovix no longer expects to receive initial volume orders this year. 

On this news, Enovix’s stock price fell $2.29 per share, or 20.23%, to close at $9.03 per share on November 6, 2025. 

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BellRing Brands, Inc. - BRBR

NEW YORK, November 5, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. (“BellRing” or the “Company”) (NYSE: BRBR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether BellRing and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On May 6, 2025, during its second quarter 2025 earnings call, BellRing revealed that certain customers were now choosing to “optimize” their inventories by lowering “their weeks of supply on hand.”  As a result, BellRing disclosed that this would slow sales growth in the third quarter to “low-single-digits.”  

On this news, BellRing’s stock price fell $14.88 per share, or 18.97%, to close at $63.55 on May 6, 2025. 

Then, on August 4, 2025, BellRing disclosed disappointing quarterly consumption of Premier Protein RTD Shakes, which had been expected to outpace shipments by a wider margin given previously announced retailer destocking, but instead came “more in line” with shipments.

On this news, BellRing’s stock price fell $17.46 per share, or nearly 33%, to close at $36.18 per share on August 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO

NEW YORK, November 5, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Alvotech (“Alvotech” or the “Company”) (NASDAQ: ALVO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Alvotech and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 2, 2025, Alvotech issued a press release “announc[ing] . . . that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech’s Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations, a biosimilar candidate to Simponi® (golimumab).”  According to the press release, “[t]he CRL noted that certain deficiencies, which were conveyed following the FDA’s pre-license inspection of Alvotech’s Reykjavik manufacturing facility that concluded in July 2025, must be satisfactorily resolved before this BLA for AVT05 can be approved.” 

On this news, Alvotech’s stock price fell $2.62 per share, or 34.25%, to close at $5.03 per share on November 3, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Simulations Plus, Inc. - SLP

NEW YORK, November 5, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Simulations Plus, Inc. (“Simulations Plus” or the “Company”) (NASDAQ: SLP).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980 

The investigation concerns whether Simulations Plus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 15, 2025, the Company hired Grant Thornton LLP as its new auditor.  Less than two months later, on June 11, 2025, Simulations Plus announced disappointing preliminary financial results for the third quarter of 2025, citing “[m]arket uncertainties surrounding funding, drug prices and potential tariffs” as “significant headwinds.” 

On this news, Simulations Plus’s stock price fell $6.39 per share, or more than 24%, to close at $20.05 per share on June 12, 2025. 

Then, on July 14, 2025, Simulations Plus reported its financial results for the third quarter of 2025, which included a $77.2 million charge “related to prior acquisitions.”  The next day, Simulations Plus reported that it had dismissed Grant Thornton, stating that “the Company (i) reviewed certain matters regarding segment reporting and reporting unit determinations, that it determined could not be finalized in time . . . , (ii) evaluated internal controls over financial reporting related to Sarbanes-Oxley Act Section 404(a) compliance, concluding they could not be finalized timely [], and (iii) there were no ‘reportable events’' as defined in Item 304(a)(1)(v) of Regulation S-K.”  However, Simulations Plus also disclosed that the auditor disagreed with the Company’s characterizations and that, according to Grant Thornton, “[it] identified and communicated certain matters to management and the Audit Committee related to segment reporting and reporting unit determinations as well as internal controls over financial reporting,” which “were not resolved to our satisfaction as of the date of our termination.” 

On this news, Simulations Plus’s stock price fell $4.50 per share, or 25.76%, to close at $12.97 per share on July 15, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

NEW YORK, November 5, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 3, 2025, Sarepta disclosed that its late-stage ESSENCE trial for two gene therapies, AMONDYS 45 (casimersen) and VYONDYS 5 (golodirsen), both aimed at treating Duchenne muscular dystrophy, “did not meet statistical significance on its primary endpoint”. 

On this news, Sarepta’s stock price fell $8.25 per share, or 33.74%, to close at $16.20 per share on November 4, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD

NEW YORK, November 5, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (NASDAQ: PRLD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Prelude and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 4, 2025, Prelude issued a press release announcing its decision to pause the clinical development of its SMARCA2 degrader program.  Prelude said that “[t]he decision to pause was based on a comprehensive review of clinical data generated to date and the Company’s assessment of the capital and resource allocation required to advance the SMARCA2 program, versus the JAK2 and KAT6A programs, to key points of value inflection.” 

On this news, Prelude’s stock price fell $2.22 per share, or 55.78%, to close at $1.76 per share on November 4, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beyond Meat, Inc. - BYND

NEW YORK, November 5, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Beyond Meat, Inc. (“Beyond Meat” or the “Company”) (NASDAQ: BYND).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Beyond Meat and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 24, 2025, Beyond Meat announced that it “expects to record a non-cash impairment charge for the three months ended September 27, 2025, related to certain of its long-lived assets,” which it “expected to be material.”  

On this news, Beyond Meat’s stock price fell $0.655 per share, or 23.06%, to close at $2.185 per share on October 24, 2025. 

Then, on November 3, 2025, Beyond Meat delayed its earnings announcement for the third quarter of 2025, citing the need for additional time to complete the impairment review. 

On this news, Beyond Meat’s stock price fell $0.275 per share, or 16.52%, to close at $1.39 per share on November 3, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alkami Technology, Inc. - ALKT

NEW YORK, November 4, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Alkami Technology, Inc. (“Alkami” or the “Company”) (NASDAQ: ALKT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Alkami and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 30, 2025, Alkami issued a press release reporting its financial results for the third quarter of 2025.  Among other items, Alkami reported GAAP earnings per share of -$0.14, missing consensus estimates by $0.02, and revenue of $113 million, missing consensus estimates by $0.48 million. 

On this news, Alkami’s stock price fell $1.70 per share, or 7.73%, to close at $20.29 per share on October 31, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savers Value Village, Inc. - SVV

NEW YORK, October 20, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Savers Value Village, Inc. (“Savers” or the “Company”) (NYSE: SVV).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Savers and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On or around June 29, 2023, Savers conducted its initial public offering (“IPO”) of 25,635,415 shares of common stock priced at $18.00 per share.  On October 30, 2025, Savers reported its financial results for the third quarter.  Although Savers reported a non-GAAP $0.14 per share profit, its financial results actually reflected a loss of $0.09 per share calculated according to GAAP. 

On this news, Savers’ stock price fell $4.02 per share, or 30.39%, to close at $9.21 per share on October 31, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC

NEW YORK, November 10, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Regencell and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 31, 2025, Regencell disclosed in a filing with the U.S. Securities and Exchange Commission that “following recent volatility in the market for our Ordinary Shares, the Company received correspondence and a subpoena from the U.S. Department of Justice (‘DOJ’), indicating that the DOJ is conducting an investigation into the trading in our Ordinary Shares.”  Regencell said that “[t]he DOJ has requested the production of documents and communications concerning these and other corporate operational, financial and accounting matters” and that the Company “expect[s] to continue to incur significant legal costs and other expenses in connection with responding to the investigation” and “may be required to pay fines, penalties, damages or settlement costs in excess of our insurance coverage, if any, related to the investigation.” 

On this news, Regencell’s stock price fell $3.09 per share, or 18.56%, to close at $13.56 per share on November 3, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of uniQure N.V. - QURE

NEW YORK, November 10, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether uniQure and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 3, 2025, uniQure issued a press release “announc[ing] that it received feedback from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington’s disease (HD).”  The press release stated that, “based on the discussions at the meeting, uniQure believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.”  uniQure described this development as “a key shift from prior communications with the FDA in multiple Type B meetings over the past year” and said that, “[c]onsequently, the timing of the BLA submission for AMT-130 is now unclear.” 

On this news, uniQure’s stock price fell $33.40 per share, or 49.34%, to close at $34.29 per share on November 3, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Owens Corning - OC

NEW YORK, November 10, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Owens Corning (“Owens Corning” or the “Company”) (NYSE: OC).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Owens Corning and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 5, 2025, Owens Corning issued a press release announcing its financial results for the third quarter of 2025.  Among other items, Owens Corning reported a net loss of $495 million, or $5.93 per diluted share, compared to net income of $287 million, or $3.26 per share, for the same period in 2025.  The net loss reflected a $780 million non-cash impairment charge tied to the Company’s doors business.  Owens Corning projected that soft residential markets and reduced storm-related roofing demand will weigh on fourth-quarter results, with revenue expected to decline to between $2.1 billion and $2.2 billion. 

On this news, Owen Corning’s stock price fell $11.69 per share, or 9.53%, to close at $111.03 per share on November 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zimmer Biomet Holdings, Inc. - ZBH

NEW YORK, November 10, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Zimmer Biomet Holdings, Inc. (“Zimmer Biomet” or the “Company”) (NYSE: ZBH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Zimmer Biomet and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On November 5, 2025, Zimmer Biomet issued a press release announcing its financial results for the third quarter of 2025 and held an earnings call to discuss the same.  Among other items, Zimmer Biomet reported net sales of $2 billion, missing consensus estimates of $2.01 billion.  Zimmer Biomet also lowered the top end of its outlook for full-year organic revenue growth, projecting gains of 3.5% to 4%, compared to a previous range of 3.5% to 4.5%.  Zimmer Biomet reported weakness in international markets and non-core businesses, while its Chief Executive Officer said that distributor challenged and a cancelation of orders in the Middle East and Eastern Europe also weighed on the Company’s results.  Analysts also noted lower-than-expected growth in U.S. knee and hip replacement sales, expressing concerns about Zimmer Biomet’s operational controls. 

On this news, Zimmer Biomet’s stock price fell $15.63 per share, or 15.5%, to close at $87.55 per share on November 5, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nidec Corporation - NJDCY

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Nidec Corporation (“Nidec” or the “Company”) (OTCMKTS: NJDCY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Nidec and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On September 3, 2025, Nidec disclosed that it had established a third-party committee to investigate suspicions of improper accounting.  The Company further revealed that its “investigations found multiple documents suggesting that . . . the Company and its group companies could have engaged in improper accounting with the involvement or knowledge of its or their management[.]” 

On this news, Nidec’s American Depositary Receipt (“ADR”) price fell $0.81 per ADR, or 16.5%, to close at $4.11 per ADR on September 4, 2025. 

Then, on September 26, 2025, Nidec disclosed further investigative findings of additional suspected inappropriate accounting practices, including “cases where the reported value for customs purposes was declared to be lower than the appropriate amount without legitimate reason.”  Nidec also revealed that it “received an audit report containing a disclaimer of opinion” from its auditor due to the “ongoing investigations by the third-party committee, other internal investigations, and other action[s].” 

On this news, Nidec’s ADR price fell $0.29 per share, or 6.6%, to close at $4.09 per ADR on September 26, 2025. 

On October 23, 2025, Nidec published a press release announcing that it was withdrawing its year-end forecast and had decided not to pay a surplus dividend, as “investigations by the Third Party Committee regarding suspected inappropriate accounting practices involving the Company and its group, as well as other internal investigations, are ongoing.” 

On this news, Nidec’s ADR price fell $1.17 per ADR, or 25.4%, to close at $3.43 per ADR on October 23, 2025. 

Finally, on October 27, 2025, the Tokyo Stock Exchange (“TSE”) designated Nidec under a Special Security alert in part because “TSE deems that the improvement of the internal management system of [Nidec] is highly necessary.”  The alert noted that “[s]ince the initial issue was discovered, the scope of the investigation has continued to expand” and that “deficiencies have already been identified in the Company’s company-wide internal control systems (particularly in areas related to information and communication), as well as in the internal controls related to its accounting and financial closing processes.” 

On this news, Nidec’s ADR price fell $0.80 per ADR, or 20.3%, to close at $3.15 per ADR on October 27, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.   

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vera Bradley, Inc. - VRA

NEW YORK, October 30, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Vera Bradley, Inc. (“Vera Bradley” or the “Company”) (NASDAQ: VRA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Vera Bradley and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On June 11, 2025, Vera Bradley announced its financial results for the first quarter of fiscal year 2026.  The Company’s Chief Executive Officer described the results as “disappointing as top line and profitability trends from the previous several quarters continued.” 

On this news, Vera Bradley’s stock price fell $0.45 per share, or 19.15%, to close at $1.90 per share on June 11, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.